Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Winslow

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Hybridoma|August 22, 2000
Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesisJ S Hongo, G R Laramee, R Urfer, et al.
Annals of Neurology|July 1, 1995
Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathyW Q Gao, N Dybdal, N Shinsky, et al.
Journal of Neurobiology|March 1, 1997
Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaineJ M Zhang, J Dix, C J Langtimm-Sedlak, et al.
Experimental Brain Research|December 3, 1998
Protein targeting in the analysis of learning and memory: a potential alternative to gene targetingR Gerlai, S P Williams, B Cairns, et al.
Neuron|May 1, 1995
Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formationJ W Winslow, P Moran, J Valverde, et al.
Biomedical & Environmental Mass Spectrometry|November 1, 1990
Structural characterization by mass spectrometry of native and recombinant human relaxinJ T Stults, J H Bourell, E Canova-Davis, et al.
Molecular and Cellular Neurosciences|August 12, 1998
Regulation of hippocampal synaptic plasticity by the tyrosine kinase receptor, REK7/EphA5, and its ligand, AL-1/Ephrin-A5W Q Gao, N Shinsky, M P Armanini, et al.
Nature Chemistry|July 8, 2020
Tunable exciton binding energy in 2D hybrid layered perovskites through donor-acceptor interactions within the organic layerJames V Passarelli, Catherine M Mauck, Samuel W Winslow, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and NeuroinflammationS K Bartholomew, J Turk, W Winslow, et al.
Ciba Foundation Symposium|January 1, 1996
Development of neurotrophic factor therapy for Alzheimer's diseaseF Hefti, M P Armanini, K D Beck, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Hybridoma|August 22, 2000
Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesisJ S Hongo, G R Laramee, R Urfer, et al.
Annals of Neurology|July 1, 1995
Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathyW Q Gao, N Dybdal, N Shinsky, et al.
Journal of Neurobiology|March 1, 1997
Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaineJ M Zhang, J Dix, C J Langtimm-Sedlak, et al.
Experimental Brain Research|December 3, 1998
Protein targeting in the analysis of learning and memory: a potential alternative to gene targetingR Gerlai, S P Williams, B Cairns, et al.
Neuron|May 1, 1995
Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formationJ W Winslow, P Moran, J Valverde, et al.
Biomedical & Environmental Mass Spectrometry|November 1, 1990
Structural characterization by mass spectrometry of native and recombinant human relaxinJ T Stults, J H Bourell, E Canova-Davis, et al.
Molecular and Cellular Neurosciences|August 12, 1998
Regulation of hippocampal synaptic plasticity by the tyrosine kinase receptor, REK7/EphA5, and its ligand, AL-1/Ephrin-A5W Q Gao, N Shinsky, M P Armanini, et al.
Nature Chemistry|July 8, 2020
Tunable exciton binding energy in 2D hybrid layered perovskites through donor-acceptor interactions within the organic layerJames V Passarelli, Catherine M Mauck, Samuel W Winslow, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and NeuroinflammationS K Bartholomew, J Turk, W Winslow, et al.
Ciba Foundation Symposium|January 1, 1996
Development of neurotrophic factor therapy for Alzheimer's diseaseF Hefti, M P Armanini, K D Beck, et al.
Pageof 11